Streetbeat News

Price Targets

FFIN

First Finl Bankshares (NASDAQ:FFIN) has been the subject of diverse analyst ratings over the past three months, with 4 indifferent ratings in total and 1 in the last 30 days. Analysts have raised their 12-month price targets, with an average of $32.25, reflecting a 9.32% increase from the previous $29.50. The company operates in community banking in Texas and has shown a -2.08% revenue decline as of December 31, 2023, but outperforms industry averages in net margin, ROE, and ROA, and has a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:01 pm

NTRA

Goldman Sachs analyst Matthew Sykes has reaffirmed a Buy rating on Natera (NASDAQ:NTRA) and increased the price target from $64 to $80.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 2:01 pm

OHI

Omega Healthcare Invts (NYSE:OHI) has been the subject of varying opinions from 5 analysts over the past three months, with recent ratings showing 1 bullish and 3 indifferent stances. The average 12-month price target is now $33.00, down from $34.00, with a high estimate of $36.00 and a low of $31.00. Analysts from Deutsche Bank, B of A Securities, Mizuho, Truist Securities, and Wells Fargo have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Omega Healthcare Investors Inc is a REIT focusing on long-term healthcare facilities, aiming to grow through M&A and maintain high care standards. The company has shown a revenue growth rate of 1.09% as of September 30, 2023, a net margin of 37.76%, an ROE of 2.51%, an ROA of 0.97%, and a debt-to-equity ratio of 1.44.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:01 pm

C

Nine analysts have recently updated their ratings on Citigroup (NYSE:C), with a mix of bullish and indifferent stances. The average 12-month price target is now $64.44, up from $59.00, with a high estimate of $93.00 and a low of $47.00. Analysts from firms including Morgan Stanley, Oppenheimer, Piper Sandler, HSBC, Wolfe Research, Barclays, and Goldman Sachs have raised their price targets. Citigroup's financial performance shows challenges with negative revenue trends, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:01 pm

MPW

Analysts have recently updated their ratings and price targets for Medical Properties Trust (NYSE:MPW), with a new average price target of $4.62, representing a 52.22% decrease from the previous target of $9.67. The ratings range from 'Sell' to 'Hold', with price targets varying from $2.00 to $7.00. The company's financial health shows a revenue decline of -12.99% over the past 3 months, a high net margin of 37.97%, and a strong ROE of 1.4%. Medical Properties Trust is a healthcare facility REIT with a lower market capitalization compared to industry averages and is considered for mergers and acquisitions as part of its growth strategy.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:00 pm

EPAM

Seven analysts have updated their ratings on EPAM Systems (NYSE:EPAM) in the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is now $295.14, up 19.39% from the previous target of $247.20. Analysts from firms including Mizuho, Morgan Stanley, Citigroup, Jefferies, and Piper Sandler have made various adjustments to their ratings and price targets. EPAM's financials show a negative revenue trend with a -6.1% growth, a strong net margin of 8.44%, a below-average ROE of 2.96%, an exceptional ROA of 2.35%, and a low debt-to-equity ratio of 0.05.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:00 pm

HLIT

Raymond James analyst Simon Leopold has maintained a Strong Buy rating on Harmonic (NASDAQ:HLIT) but reduced the price target from $19 to $18.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 2:00 pm

NPCE

NeuroPace (NASDAQ:NPCE) has been analyzed by 6 analysts, showing a mix of bullish to indifferent sentiments. The average 12-month price target is $11.83, a significant increase from the previous $8.00. Analysts from firms like Leerink Partners, Lake Street, Morgan Stanley, Cantor Fitzgerald, and JP Morgan have provided ratings and adjusted price targets. NeuroPace is a medical device company focusing on epilepsy treatments, with recent revenue growth of 47.23% and a market cap below industry average. The company has a high debt-to-equity ratio of 4.38, and its ROE and ROA are below industry standards.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 2:00 pm

MYGN

Goldman Sachs analyst Matthew Sykes has reaffirmed a Buy rating on Myriad Genetics (NASDAQ:MYGN) and increased the price target from $28 to $31.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 1:59 pm

GH

Goldman Sachs analyst Matthew Sykes has maintained a Buy rating on Guardant Health (NASDAQ:GH) but reduced the price target from $43 to $37.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 1:58 pm